A comparative analysis of infection in patients with malignant cancer: A clinical pharmacist consultation study
Background: Infection analysisamongst malignant cancer patients remains elusive. The objective of this study is to investigate the characteristics of both infection and anti-infection treatments in patients group with malignant cancer. Methods: We retrospectively studied the clinical data of 148 pat...
Main Authors: | , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2019-11-01
|
Series: | Journal of Infection and Public Health |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1876034119301303 |
id |
doaj-93454356824b43a1b95c269b1e1a4cf6 |
---|---|
record_format |
Article |
spelling |
doaj-93454356824b43a1b95c269b1e1a4cf62020-11-25T02:47:48ZengElsevierJournal of Infection and Public Health1876-03412019-11-01126789793A comparative analysis of infection in patients with malignant cancer: A clinical pharmacist consultation studyLi Lin0Lihua Jia1Yali Fu2Ruonan Zhao3Yuan Huang4Chuanhao Tang5Chao Meng6Dazhong Zhao7Jun Liang8Department of Oncology, Peking University International Hospital, Beijing 102206, ChinaDepartment of Pharmacy, Beijing Electric Power Hospital, State Electric Grid Co., Beijing 100071, ChinaDepartment of Oncology, Peking University International Hospital, Beijing 102206, ChinaMedical Department, Beijing Electric Power Hospital, State Electric Grid Co., Beijing 100071, ChinaDepartment of Clinical Laboratory, Fifth Medical Center of Chinese PLA General Hospital, Beijing 100071, ChinaDepartment of Oncology, Peking University International Hospital, Beijing 102206, ChinaDepartment of Oncology, Peking University International Hospital, Beijing 102206, ChinaDepartment of Orthopedic, Beijing Electric Power Hospital, State Electric Grid Co., Beijing 100071, ChinaDepartment of Oncology, Peking University International Hospital, Beijing 102206, China; Corresponding author.Background: Infection analysisamongst malignant cancer patients remains elusive. The objective of this study is to investigate the characteristics of both infection and anti-infection treatments in patients group with malignant cancer. Methods: We retrospectively studied the clinical data of 148 patients with malignant cancer and 171 benign patients enrolled in the pharmacist consultation from April 2015 to April 2017. Statistical analysis was performed by chi-square test to compare the classification of primary disease, sites of infection, composition of pathogenic bacteria, and the effectiveness of drug treatment. P value <0.05 was considered statistically significant. Results: A total of 102 pathogen strains were detected in the patients with malignant cancer and 129 pathogen strains were noted in the benign patient group, respectively. Statistics indicated that more abdominal infections were observed in malignant cancer patients rather than in non-cancer patients. Additionally, more pseudomonas aeruginosa infection was found in the malignant cancer patient group while more Klebsiella pneumonia infection was noted in the benign group. These findings were supported by statistical evidence. There were fewer extended-spectrum β-lactamases (ESBL) that produced Escherichia coli, which was commonly found in a gastrointestinal cancer patient group compared to patients under other types of cancer; it accounted for 51.3% of all malignant cases involved in the current study. Conclusions: Patients with malignant cancer are more likely to suffer from an infection containing pathogenic bacteria in comparison to benign patients. There have been considerable differences in the composition of pathogenic bacteria and its resistance to drugs. Overall, evaluating pathogens plays an essential role in the anti-infection treatment of patients with malignant cancer. Keywords: Infection, Malignant cancer, Pathogenic bacteria, Pharmacist consultation, Statistical analysishttp://www.sciencedirect.com/science/article/pii/S1876034119301303 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Li Lin Lihua Jia Yali Fu Ruonan Zhao Yuan Huang Chuanhao Tang Chao Meng Dazhong Zhao Jun Liang |
spellingShingle |
Li Lin Lihua Jia Yali Fu Ruonan Zhao Yuan Huang Chuanhao Tang Chao Meng Dazhong Zhao Jun Liang A comparative analysis of infection in patients with malignant cancer: A clinical pharmacist consultation study Journal of Infection and Public Health |
author_facet |
Li Lin Lihua Jia Yali Fu Ruonan Zhao Yuan Huang Chuanhao Tang Chao Meng Dazhong Zhao Jun Liang |
author_sort |
Li Lin |
title |
A comparative analysis of infection in patients with malignant cancer: A clinical pharmacist consultation study |
title_short |
A comparative analysis of infection in patients with malignant cancer: A clinical pharmacist consultation study |
title_full |
A comparative analysis of infection in patients with malignant cancer: A clinical pharmacist consultation study |
title_fullStr |
A comparative analysis of infection in patients with malignant cancer: A clinical pharmacist consultation study |
title_full_unstemmed |
A comparative analysis of infection in patients with malignant cancer: A clinical pharmacist consultation study |
title_sort |
comparative analysis of infection in patients with malignant cancer: a clinical pharmacist consultation study |
publisher |
Elsevier |
series |
Journal of Infection and Public Health |
issn |
1876-0341 |
publishDate |
2019-11-01 |
description |
Background: Infection analysisamongst malignant cancer patients remains elusive. The objective of this study is to investigate the characteristics of both infection and anti-infection treatments in patients group with malignant cancer. Methods: We retrospectively studied the clinical data of 148 patients with malignant cancer and 171 benign patients enrolled in the pharmacist consultation from April 2015 to April 2017. Statistical analysis was performed by chi-square test to compare the classification of primary disease, sites of infection, composition of pathogenic bacteria, and the effectiveness of drug treatment. P value <0.05 was considered statistically significant. Results: A total of 102 pathogen strains were detected in the patients with malignant cancer and 129 pathogen strains were noted in the benign patient group, respectively. Statistics indicated that more abdominal infections were observed in malignant cancer patients rather than in non-cancer patients. Additionally, more pseudomonas aeruginosa infection was found in the malignant cancer patient group while more Klebsiella pneumonia infection was noted in the benign group. These findings were supported by statistical evidence. There were fewer extended-spectrum β-lactamases (ESBL) that produced Escherichia coli, which was commonly found in a gastrointestinal cancer patient group compared to patients under other types of cancer; it accounted for 51.3% of all malignant cases involved in the current study. Conclusions: Patients with malignant cancer are more likely to suffer from an infection containing pathogenic bacteria in comparison to benign patients. There have been considerable differences in the composition of pathogenic bacteria and its resistance to drugs. Overall, evaluating pathogens plays an essential role in the anti-infection treatment of patients with malignant cancer. Keywords: Infection, Malignant cancer, Pathogenic bacteria, Pharmacist consultation, Statistical analysis |
url |
http://www.sciencedirect.com/science/article/pii/S1876034119301303 |
work_keys_str_mv |
AT lilin acomparativeanalysisofinfectioninpatientswithmalignantcanceraclinicalpharmacistconsultationstudy AT lihuajia acomparativeanalysisofinfectioninpatientswithmalignantcanceraclinicalpharmacistconsultationstudy AT yalifu acomparativeanalysisofinfectioninpatientswithmalignantcanceraclinicalpharmacistconsultationstudy AT ruonanzhao acomparativeanalysisofinfectioninpatientswithmalignantcanceraclinicalpharmacistconsultationstudy AT yuanhuang acomparativeanalysisofinfectioninpatientswithmalignantcanceraclinicalpharmacistconsultationstudy AT chuanhaotang acomparativeanalysisofinfectioninpatientswithmalignantcanceraclinicalpharmacistconsultationstudy AT chaomeng acomparativeanalysisofinfectioninpatientswithmalignantcanceraclinicalpharmacistconsultationstudy AT dazhongzhao acomparativeanalysisofinfectioninpatientswithmalignantcanceraclinicalpharmacistconsultationstudy AT junliang acomparativeanalysisofinfectioninpatientswithmalignantcanceraclinicalpharmacistconsultationstudy AT lilin comparativeanalysisofinfectioninpatientswithmalignantcanceraclinicalpharmacistconsultationstudy AT lihuajia comparativeanalysisofinfectioninpatientswithmalignantcanceraclinicalpharmacistconsultationstudy AT yalifu comparativeanalysisofinfectioninpatientswithmalignantcanceraclinicalpharmacistconsultationstudy AT ruonanzhao comparativeanalysisofinfectioninpatientswithmalignantcanceraclinicalpharmacistconsultationstudy AT yuanhuang comparativeanalysisofinfectioninpatientswithmalignantcanceraclinicalpharmacistconsultationstudy AT chuanhaotang comparativeanalysisofinfectioninpatientswithmalignantcanceraclinicalpharmacistconsultationstudy AT chaomeng comparativeanalysisofinfectioninpatientswithmalignantcanceraclinicalpharmacistconsultationstudy AT dazhongzhao comparativeanalysisofinfectioninpatientswithmalignantcanceraclinicalpharmacistconsultationstudy AT junliang comparativeanalysisofinfectioninpatientswithmalignantcanceraclinicalpharmacistconsultationstudy |
_version_ |
1724751176131411968 |